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 Background: Although some studies have shown positive effects of omega-3 fatty 
acid supplementation on nutritional status of cancer patients undergoing different 
treatments, there is no consistency in results. The aim of this study was to examine 
the effects of omega-3 fatty acid on the nutritional status of gastric cancer patients 
during the course of chemotherapy. 
Methods: In a double-blind clinical trial, 30 adult patients with gastric cancer 
receiving chemotherapy were randomized into a supplement and a placebo groups 
and given daily, for 6 weeks, a 3-g omega-3 fatty acid supplement (containing 1.8g 
eicosapentaeonic plus 1.2g docosahexaenoic acid) and oral paraffin, respectively. 
Anthropometric data was collected and nutritional status assessed at the beginning, 
at week 4 and at the end of week 6. The data were analyzed using repeated 
measures ANOVA and independent sample t-test. 
Results: The findings indicated that omega-3 fatty acid supplementation increased 
body weight, mean daily intake of  energy and macronutrients, serum levels of 
transferrin and albumin at the end of the 6-week period significantly (p<0.05). All 
these variables decreased in the placebo group (p<0.05). The increases in body 
weight, energy and carbohydrate intakes, and serum levels of albumin in the 
supplement group were time-dependent (p<0.05). 
Conclusion: The results of present study showed that omega-3 fatty acid 
supplementation can improve nutritional status in patients with gastric cancer 
during the course of chemotherapy. We recommend using omega-3 fatty acid 
supplement in patients with gastric cancer during chemotherapy. 
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Introduction 
The global incidence of malnutrition in 
cancer patients ranges from 30% to 85%, being 
most prevalent in patients with gastric, 
pancreatic, lung, prostate and colon cancer [1,2]. 
Besides several variables such as age, gender 
and individual susceptibilities, malnutrition also 
affects anticancer treatments and disease 
symptoms. Prolonged under-nutrition can result 
in cachexia, involuntary body weight loss with 
depletion of lean body mass, muscle wasting, 
               _________________________________________ 
Corresponding author: 
Dr Iraj Faizi-Khankandi, M.D. 
Address: Department of Internal Disease, School of 
Medicine, Ardabil University of Medical Sciences, 
Ardabil, Iran. 
Email: i.feizi@arums.ac.ir  
 
Ali Nemati, et al.  
JNSD 2014; Vol.1, No. 1                                                                                   3  
 
weakness [3], impaired response to 
chemotherapy [4,5], susceptibility to 
chemotherapy-induced toxicity [5,6], decrement 
of life quality and increment of morbidity and 
mortality [7]. An inadequate nutritional intake 
occurs frequently in cancer patients who fail to 
cope with increasing resting energy demands. 
The reduced food intake and metabolic change 
are vitally important in patients with cancer 
cachexia [8]. Providing nutritional support may 
be useful in aspect of minimizing gastrointestinal 
symptoms and improving life quality. Nutritional 
supplementation in adequately nourished 
patients delays the progression of malnutrition 
[9], improves immune function [2,10] and 
performance status [11,12]. It has been shown 
that the fish oil inhibits inflammation in vivo and 
is associated with weight gain, better response to 
therapy, fewer complications and even improved 
survival in some patients [13,14]. Studies on 
animals are quite promising, indicating that 
omega-3 fatty acid may be a clinically useful 
supplement to cancer therapy. The dose of 
omega-3 fatty acid used in animal studies have 
been very high, often 20–24% (by weight) of the 
diet. However, their results may convince the 
clinical researchers to use omega-3 fatty acid 
supplements for human treatment, although the 
mechanism of action is still under investigation 
and the optimum level of omega-3 fatty acids to 
suppress cancer growth [15] is yet to be 
determined. In this study, we examined effects 
of omega-3 fatty acid intake on anthropometric 
measurements, biochemical factors and food 
intake in patients with gastric cancer during 
chemotherapy. 
 
 Methods 
Study design and population 
This double blind clinical trial study was 
conducted in Nutrition Research Center of 
Tabriz University of Medical Sciences, Iran, 
2010 - 2011. The study was approved by the 
Medical Ethical Committee of the Tabriz 
University of Medical Sciences and registered 
under identification code of IRCT 
201011095144N1 in Iranian Registry of Clinical 
Trials. Thirty adult patients over 30 years old at 
different stages of malignancies of gastric cancer 
undergoing chemotherapy were randomly 
selected from Imam and Fatemi Hospitals of 
Ardabil city. The aims and study protocol were 
explained to the subjects and a written consent 
was taken from all participants. Only patients 
over 30 years old were selected and were divided 
into two groups of supplement and placebo. 
Subjects with diseases inducing cachexia such as 
heart, lung and renal diseases, AIDS, acute 
leukemia, diabetes, multiple myeloma, and 
individuals undergoing surgery were excluded. 
The staging procedure, based on imaging results 
of cancer, was used for patients with gastric 
cancer, and only stages II and III were included 
in the study. Data on anthropometric indices and 
biochemical parameters were collected in the 
beginning, middle and at the end of the 
chemotherapy period, and changes in weight, 
body mass index (BMI), and biochemical 
parameters were calculated for both groups. The 
supplement group received 3 times daily for 6 
weeks, 3g omega-3 fatty acids (containing 1.8g 
eicosapentaenoic (EPA) and 1.2g 
docosahexaenoic acid (DHA)) (Herron-Sigma) 
in 10g fish oil,  while the placebo group were 
given paraffin.  Each tablet containing of 
eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) was 180 mg and 
120 mg in 1 gram fish oil, respectively. Fasting 
blood samples were taken at the beginning and 
after 4 and 6 weeks by venipuncture and the sera 
separated. All samples were kept frozen at – 80 
0C until analyzed. Also, at the beginning and 
after 4 and 6 weeks, the nutritional status of the 
subjects was assessed using anthropometric 
measurements such as height, weight (current 
and usual weight), biochemical parameters 
(albumin and transferrin), and food intake 
determined. The BMI was calculated using the 
data recorded for height and weight. 
 
Treatment schedule 
The chemotherapy regimen consisted of 3 
weeks of interval docetaxel (Taxotere; Sanofi-
aventis, Bridgewater, NJ) 75 mg/m2 (day 1) plus 
cisplatin 75 mg/m2 (day 1) and fluorouracil 750 
mg/m2/d continuous infusion (days 1 to 5; DCF) 
according to Ajani's protocol [16]. 
 
Nutritional assessment 
The usual body weight of the patients was 
asked and recorded at the start of the study. 
Body weight and BMI were measured for all 
patients at the beginning, middle and at the end 
of the study. Height and weight were obtained 
using a portable digital scale and portable digital 
stadiometer. Food intake changes were recorded 
using 24-hour dietary recalls for three days (2 
weekdays and 1 weekend day) before treatment, 
and 4 and 6 weeks after intervention. Mean daily 
dietary intake and food composition were 
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estimated using Nutritionist IV. Fasting blood 
samples were taken for measurement of 
transferrin and albumin before treatment, 4 and 6 
weeks after intervention. Serum albumin and 
transferrin concentrations were measured by 
routine laboratory procedures. For all volunteers 
the nutritional risk index (NRI) was determined 
before intervention using the formula NRI= 
(1.489 × serum albumin, g/l) +41.7 × (current 
weight/usual weight)  
A NRI>100 indicates that the patient is not 
malnourished, 97.5-100 indicates mild, 83.5-
97.5 moderate and <83.5 severe malnourishment 
[17,18]. 
 
Statistical analysis 
Repeated measures ANOVA, paired sample 
t-test and independent sample t-test were used 
for data analysis in SPSS (version 14). Results 
are expressed as mean ± SD. Significant changes 
were assumed significant at p<0.05. 
 
Results 
Most of the patients with gastric cancer 
undergoing chemotherapy had moderate to 
severe malnutrition (Fig. 1.) The biochemical 
and anthropometric variables at different times 
are shown in Table 1. The results indicated that, 
as compared to the placebo group, omega 3 fatty 
acids significantly increased body weight and 
mean serum levels of transferrin and albumin of 
patients in the supplement group (in all cases 
p<0.05).  
 
Figure 1. Nutritional status of the subjects before the intervention 
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Table 1. Comparison of anthropometric and biochemical variables between the supplement and placebo groups 
 Time measured Supplement 
(n=15) 
Placebo 
 (n=15) 
p-value 
Weight (kg) Before intervention 56.7 ±  10.2 56.2 ±  6.9 0.86 
After 4 weeks 58.3 ±  9.4* 54.3 ±  6.6* 0.18 
End of Week 6 59.2 ±  8.9** 52.6 ±  5.6** 0.02● 
BMI (kg/m2) Before intervention 20.4  ± 2.7 20.6  ± 2.6 0.85 
After 4 weeks 20.9 ±  2.5* 19.9 ±  2.4* 0.26 
End of Week 6 21.1 ±  2.4** 19.5 ±  2.4** 0.08 
Serum albumin 
(mg/dl) 
Before intervention 3.82 ± 0.22 3.87 ± 0.26 0.56 
After 4 weeks 3.88 ± 0.26 3.93 ± 0.24 0.61 
End of Week 6 4.1 ± 0.34** 3.86 ± 0.25 0.01● 
Serum transferrin 
(mg/dl) 
Before intervention 226.8 245.7 0.052 
After 4 weeks 228.4 231.4 0.75 
End of Week 6 242.4 214.8** 0.03● 
Values are mean ±SD, *P <0.05 vs baseline, ** P<0.05 vs 4 weeks  
●p <0.05 in independent sample T-test between the two groups 
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 The body weight and energy and 
carbohydrate intakes, as well as serum levels of 
albumin also significantly increased in the 
supplemented group during the study (p<0.05), 
while they decreased in the placebo group during 
study period (p<0.05). The mean daily intakes of 
energy, carbohydrate, fat, protein, fatty acids 
(saturated, monounsaturated, and 
polyunsaturated fatty acids),  fiber, and  
cholesterol in the supplemented group were 
higher than in the placebo group at the end of 
study (p<0.05) (Table 2). There was no 
significant difference between the two groups in 
terms of mean dietary omega-3 fatty acids. Daily 
micronutrient intakes of the subjects are shown 
in Table 3. It is seen that the mean daily intakes 
of vitamin A, potassium, copper and selenium in 
the supplement group were significantly higher 
than those in the placebo group at the end of 
week 6 (p<0.05); in the case of other nutrients no 
significant differences were observed.  
 
Discussion 
Our findings showed that  80% of the patients 
had moderate to severe malnutrition which is 
consistent with reports from previous studies [1-
2, 19]. Malnutrition can lead to increased risk of 
morbidity, decline in chemotherapy response and 
weakness of the immune system, as well as 
shorter survivals in cancer patients [20]. Various 
nutritional interventions for the prevention of 
malnutrition have been performed in gastric 
cancer patients [21,22]. Dietary omega-3 fatty 
acid supplementation is recommended for them 
[23]. These fatty acids, present in large amounts 
in fish oil, actively reduce either tumor growth 
Table 2. Comparison of daily energy, macronutrients, fiber and cholesterol intakes between the placebo and 
supplement groups during the study 
 Variables Time measured    Supplement  
(n=15)
Placebo 
 (n=15) 
p-value 
Energy (kcal/day) Before 1651 ±  183 1734 ±  164 0.2 
After 4 weeks 1692 ±  180* 1597 ±  183* 0.16 
End of Week 6 1793 ±  130** 1408 ±  255** 0.01● 
CHO  (g/day) Before 232 ± 40 267 ± 33 0.14 
After 4 weeks 259 ± 30* 258 ± 35 0.92 
End of Week 6 269 ± 37* 218 ± 48** 0.03● 
Fat  (g/day) Before 47 ± 11 49 ± 16 0.81 
After 4 weeks 47 ± 11 45 ± 10* 0.16 
End of Week 6 49 ± 11 38 ±  12* 0.01 
Protein  (g/day) Before 73 ± 22 58 ± 20 0.055 
After 4 weeks 74 ± 22 57 ± 15 0.02● 
End of Week 6 75 ± 14 49 ± 18 0.01● 
Saturated fatty acids 
(g/day) 
Before 10 ± 3 11 ±  6 0.71 
After 4 weeks 11 ± 5 9 ± 4 0.58 
End of Week 6 12 ± 4 8 ± 3 0.04● 
Polyunsaturated fatty 
acid(g/day) 
Before 6 ± 2 6 ± 3 0.07 
After 4 weeks 6 ± 2 5 ±  2 0.49 
End of Week 6 7 ± 3 5 ± 2 0.02● 
Monounsaturated 
fatty acid(g/day) 
Before 12 ± 4 12 ± 5 0.06 
After 4 weeks 14 ±  5 11 ± 4 0.8 
End of Week 6 15  ± 4 11 ± 4 0.03● 
Fiber (g/day) Before 7 ± 4 6 ± 2 0.27 
After 4 weeks 7 ±  1 6 ± 2 0.38 
End of Week 6 8  ± 3 5 ± 2 0.02● 
Cholesterol (mg/day) Before 210 ± 135 164 ± 117 0.08 
After 4 weeks 254 ±  115 125 ± 52 0.03● 
End of Week 6 274  ± 208 121 ± 39 0.01● 
EPA (g/day) Before 0.007 ± 0.003 0.0075 ± 0.001 0.41 
After 4 weeks 0.008 ±  0.003 0.007 ± 0.0027 0.58 
End of Week 6 0.0085  ± 0.0002 0.0069 ± 0.0001 0.14 
DHA (g/day) Before 0.0055 ± 0.0011 0.0059 ± 0.0012 0.06 
After 4 weeks 0.0059 ±  0.003 0.0052 ± 0.0027 0.8 
End of Week 6 0.0061  ± 0.0001 0.0051 ± 0.0001 0.13 
CHO= Carbohydrate, Pr= Protein, Values are mean ±SD, *p<0.05 vs baseline, ** p<0.05 vs4 weeks in Repeated Measures 
ANOVA, ●p<0.05 in independent sample T-test between the two groups 
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or the associated tissue wasting, particularly that 
of the adipose mass [24]. Our findings 
demonstrated that omega-3 fatty acid 
supplementation can be quite effective in 
patients with gastric cancer. The intention-to-
treat analysis of a recent prospective randomized 
trial in 200 patients with pancreatic cancer 
showed that intake of high-energy, high protein 
sip feeding (600 kcal/day, 32 g protein), 
irrespective of supplementation with omega-3-
fatty acids and antioxidants resulted in stable 
body weights of the subjects [25]. Similar to 
previous studies we found that supplementation 
with omega-3 fatty acid significantly increased 
the body weight, energy, carbohydrate and 
protein intakes in gastric cancer patients [26,27]. 
Although Mario et al. observed no positive 
effects resulting from omega-3 fatty acids 
supplementation with regard to body weight and 
energy and dietary intakes in healthy subjects 
[28], most of the other studies have reported 
positive effects of this supplement [22,25]. An 
increase in body weight can be due to the fact 
that dietary supplementation of omega-3 fatty 
acids attenuates the adverse secondary effects to 
chemotherapy such as anorexia [29]. We 
Table 3. Comparison of daily vitamin and mineral intakes between the placebo and supplement groups 
during the study 
Variables Time measured Supplement 
(n=15)
Placebo 
(n=15)
p-value 
Vitamin A (RE/day) Before 244 ±  108 316 ±  171 0.06 
After 4 weeks 248 ±  108 182 ±  177* 0.002 
End of Week 6 354 ±  273* 118 ±  93** 0.00● 
Vitamin E  (mg/day) Before 10 ± 3 9 ± 3 0.16 
After 4 weeks 11 ± 3 9 ± 3 0.43 
End of Week 6 11 ± 3 9 ± 3 0.77 
Vitamin C  (mg/day) Before 36 ± 20 37 ± 13 0.67 
After 4 weeks 40 ± 16 32 ± 29 0.17 
End of Week 6 43 ± 23 30 ±  8 0.02● 
Vitamin B1  (mg/day) Before 1.1 ± 0.18 1.1 ±  0.28 0.67 
After 4 weeks 1.2 ± 0.23 1.1 ± 0.25 0.25 
End of Week 6 1.2 ± 0.25 0.9 ±  0.23 0.01● 
Vitamin B2  (mg/day) Before 1.1 ± 0.84 0.99 ±  0.39 0.2 
After 4 weeks 1.1 ± 0.3 0.65 ± 0.25 0.03● 
End of Week 6 1.4 ± 0.83 0.59 ± 0.19 0.01● 
Vitamin B3  (mg/day) Before 20 ± 5 17 ± 6 0.14 
After 4 weeks 21 ± 10 19 ±  7 0.43 
End of Week 6 23 ± 15 14 ± 8 0.04● 
Vitamin B5  (mg/day) Before 2.1 ± 0.94 2.2 ± 1.2 0.22 
After 4 weeks 2.4 ±  0.96 1.6 ± 0.69 0.07 
End of Week 6 3.1  ± 2.7 1 ± 0.39 0.01● 
Vitamin B6  (mg/day) Before 0.73 ± 0.37 0.72 ± 0.46 0.24 
After 4 weeks 0.76 ±  0.32 0.70 ± 0.39 0.85 
End of Week 6 0.90 ± 0.37 0.47 ± 0.22 0.01● 
Vitamin B12  (mg/day) Before 2.2 ± 1.1 2.2 ± 1 0.13 
After 4 weeks 2.7 ±  1.5 1.9 ± 1.1 0.42 
End of Week 6 3.3  ± 2.6 1.9 ± 0.9 0.12 
Folacin  (mg/day) Before 47 ± 19 75 ± 34 0.17 
After 4 weeks 54 ±  21 31 ± 13 0.01● 
End of Week 6 85  ± 78 23 ± 5 0.01● 
Calcium  (mg/day) Before 441 ± 188 400 ± 198 0.55 
After 4 weeks 454 ±  243 340 ± 143 0.07 
End of Week 6 458  ± 250 316 ± 170 0.13 
Phosphorous  (mg/day) Before 540 ± 170 496 ± 159 0.08 
After 4 weeks 543 ±  133 396 ± 176 0.02● 
End of Week 6 623  ± 195 373 ± 131 0.01● 
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observed that dietary supplementation with 3g of 
omega-3 fatty acids significantly increases the 
mean body weight, serum levels of albumin and 
transferrin, as well as intakes of energy and 
some macronutrients during chemotherapy. This 
finding confirms the positive effect of omega-3 
fatty acids in improving the nutritional status of 
gastric cancer patients. Although the exact 
mechanism of omega-3 fatty acids in improving 
nutritional status and body weight of patients 
with gastric cancer is not known, it is suggested 
that omega-3 fatty acids can improve the 
nutritional status through influencing the 
nervous cell membrane, cytokine production and 
hypothalamic neurotransmitters [30]. Changes in 
the chemical composition of the cell membrane 
phospholipids may modify some properties of 
cell membranes such as secondary messages, 
neurotransmitters and transitional proteins and, 
thus, inhibit inflammatory cytokine production 
[28]. Since cytokines induce anorexia, body 
weight loss, wasting energy, loss of muscle 
protein and release of leptin, and damage the 
feeding centers in hypothalamus, their reduced 
production would improve the nutritional status 
of gastric cancer patients [31]. 
 
Conclusion 
Our study demonstrated that the omega-3 
fatty acids supplementation increases body 
weight and intakes of energy and some 
macronutrients in patients with gastric cancer 
and, thus, can be an excellent adjunct therapy for 
these patients during chemotherapy. Available 
evidence indicates that increased dietary intake 
of omega-3 fatty acids can lead to longer cancer 
survival by increasing energy and nutrient 
intakes and serum albumin level.  
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